Single and Repeated Dose Escalation Study of GSK2838232

GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.

GSK2838232 will be available as film-coated tablet for oral use

GSK2838232 will be available as film-coated tablet for oral use

Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.

It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.